LLY Overview
Upcoming Projects (LLY)
-
A Third Perspective Discussing the expanding market opportunity with regard to direct to consumer platforms in the pharmaceutical space.
Tickers: PFE, LLY, VKTX, HIMS
Execute By: Oct 18, 2024
Executed Projects (LLY)
-
Obesity/Diabetes Series-October 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Oct 16, 2024 at 09:30 AM EDT -
Obesity/Diabetes Series-October 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Oct 11, 2024 at 03:00 PM EDT -
Obesity/Diabetes Series-October 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Oct 10, 2024 at 05:00 PM EDT -
A Third View: Discussing the recent FDA approval of Lilly's EBGLYSS (lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis.
Ticker: LLY
Executed On: Oct 07, 2024 at 03:00 PM EDT -
Obesity/Diabetes Series-October 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Oct 04, 2024 at 04:30 PM EDT -
A Second View: Discussing the recent FDA approval of Lilly's EBGLYSS (lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis.
Ticker: LLY
Executed On: Oct 03, 2024 at 03:00 PM EDT -
Obesity/Diabetes Series-September 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Sep 25, 2024 at 04:00 PM EDT -
Discussing the recent FDA approval of Lilly's EBGLYSS (lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis.
Ticker: LLY
Executed On: Sep 20, 2024 at 12:30 PM EDT -
Obesity/Diabetes Series-September 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Sep 19, 2024 at 10:30 AM EDT -
A Second Perspective Discussing the expanding market opportunity with regard to direct to consumer platforms in the pharmaceutical space.
Tickers: PFE, LLY, VKTX, HIMS
Executed On: Sep 18, 2024 at 09:00 AM EDT -
Discussing the expanding market opportunity with regard to direct to consumer platforms in the pharmaceutical space.
Tickers: LLY, PFE, VKTX, HIMS
Executed On: Sep 17, 2024 at 09:00 AM EDT -
A Third Look: Discussing the potential of a blood biomarker test to detect Alzheimer's disease and how it may impact the treatment landscape.
Tickers: BIIB, LLY, C2N Diagnostics
Executed On: Sep 14, 2024 at 09:30 AM EDT -
Obesity/Diabetes Series-September 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Sep 13, 2024 at 01:30 PM EDT -
A Third Opinion: Discussing the potential of Semaglutide as a treatment option for heart failure based off the results from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials.
Tickers: NVO, LLY
Executed On: Sep 12, 2024 at 10:30 AM EDT -
A Second Opinion: Discussing the potential of Semaglutide as a treatment option for heart failure based off the results from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials.
Tickers: NVO, LLY
Executed On: Sep 06, 2024 at 09:00 AM EDT -
Discussing the SURMOUNT-1 Phase 3 study of tirzepitide indicating the risk of developing type 2 diabetes in pre-diabetic adults
Ticker: LLY
Executed On: Sep 04, 2024 at 10:00 AM EDT -
Discussing the potential of Semaglutide as a treatment option for heart failure based off the results from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials.
Tickers: NVO, LLY
Executed On: Sep 04, 2024 at 08:00 AM EDT -
Obesity/Diabetes Series-August 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Aug 30, 2024 at 04:30 PM EDT -
A Third View: Digging into the phase 2b trial of liraglutide in patients with Alzheimer's disease
Tickers: NVO, BIIB, LLY
Executed On: Aug 30, 2024 at 11:00 AM EDT -
A Second Look: Discussing the potential of a blood biomarker test to detect Alzheimer's disease and how it may impact the treatment landscape.
Tickers: C2N DIAGNOSTICS, LLY, BIIB
Executed On: Aug 29, 2024 at 09:00 AM EDT -
A Third Look: Discussing the potential of Novo Nordisk's Cannabinoid blocker, INV 202 for obesity treatment
Tickers: NVO, LLY
Executed On: Aug 21, 2024 at 04:00 PM EDT -
A Second Opinion: Discussing the potential of Novo Nordisk's Cannabinoid blocker, INV 202 for obesity treatment
Tickers: NVO, LLY
Executed On: Aug 21, 2024 at 02:00 PM EDT -
A Second View: Digging into the phase 2b trial of liraglutide in patients with Alzheimer's disease
Tickers: NVO, BIIB, LLY
Executed On: Aug 20, 2024 at 04:00 PM EDT -
Digging into the phase 2b trial of liraglutide in patients with Alzheimer's disease
Tickers: NVO, BIIB, LLY
Executed On: Aug 20, 2024 at 11:00 AM EDT -
Obesity/Diabetes Series-August 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Aug 16, 2024 at 10:00 AM EDT -
Discussing the potential of Novo Nordisk's Cannabinoid blocker, INV 202 for obesity treatment
Tickers: NVO, LLY
Executed On: Aug 15, 2024 at 09:30 AM EDT -
A Second View: Checking in with a prescriber of Eli Lilly's Olumiant (baricitinib) for the treatment of COVID-19.
Ticker: LLY
Executed On: Aug 13, 2024 at 03:00 PM EDT -
Checking in with a prescriber of Eli Lilly's Olumiant (baricitinib) for the treatment of COVID-19.
Ticker: LLY
Executed On: Aug 08, 2024 at 05:30 PM EDT -
A Third Opinion: Looking at the use of Rezdiffra for MASH and reviewing the recent data on Tirzepatide from Eli Lilly
Tickers: MDGL, LLY
Executed On: Aug 07, 2024 at 10:00 AM EDT -
A Second Opinion: Looking at the use of Rezdiffra for MASH and reviewing the recent data on Tirzepatide from Eli Lilly
Tickers: MDGL, LLY
Executed On: Aug 07, 2024 at 08:00 AM EDT -
A Third View: Delving into the Phase III SUMMIT clinical trial of tirzepatide in patients with heart failure
Ticker: LLY
Executed On: Aug 06, 2024 at 05:30 PM EDT -
A Second View: Delving into the Phase III SUMMIT clinical trial of tirzepatide in patients with heart failure
Ticker: LLY
Executed On: Aug 06, 2024 at 11:30 AM EDT -
Discussing the potential of a blood biomarker test to detect Alzheimer's disease and how it may impact the treatment landscape.
Tickers: C2N DIAGNOSTICS, LLY, BIIB
Executed On: Aug 05, 2024 at 04:00 PM EDT -
Delving into the Phase III SUMMIT clinical trial of tirzepatide in patients with heart failure
Ticker: LLY
Executed On: Aug 02, 2024 at 09:00 AM EDT -
Looking at the use of Rezdiffra for MASH and reviewing the recent data on Tirzepatide from Eli Lilly
Tickers: LLY, MDGL
Executed On: Aug 01, 2024 at 11:00 AM EDT -
A Second Opinion: Speaking on the potential of Alzheon Inc's investigational oral agent ALZ-801/valiltramiprosate for Alzheimer's Disease
Tickers: ALZHEON INC., ESAIY, BIIB, LLY
Executed On: Jul 25, 2024 at 06:00 PM EDT -
A fourth look discussing how coverage, access, and pricing are evolving and being considered for GLP-1 obesity drugs, with a focus on Wegovy and Zebound.
Tickers: LLY, NVO
Executed On: Jul 25, 2024 at 12:00 PM EDT -
A Third Opinion: Discussing the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy.
Tickers: GUTS, NVO, LLY
Executed On: Jul 25, 2024 at 11:30 AM EDT -
A Second Opinion: Discussing the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy.
Tickers: GUTS, NVO, LLY
Executed On: Jul 25, 2024 at 08:30 AM EDT -
A Third Opinion: Evaluating tirzepatide's potential as a treatment for obstructive sleep apnea and obesity.
Ticker: LLY
Executed On: Jul 24, 2024 at 03:00 PM EDT -
A Third Look: Discussing the results of a new observational study published in JAMA " Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity".
Tickers: LLY, NVO
Executed On: Jul 24, 2024 at 01:00 PM EDT -
A third look discussing how coverage, access, and pricing are evolving and being considered for GLP-1 obesity drugs, with a focus on Wegovy and Zebound.
Tickers: LLY, NVO
Executed On: Jul 23, 2024 at 05:00 PM EDT -
Obesity/Diabetes Series-July 2024 (5): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 22, 2024 at 05:00 PM EDT -
Obesity/Diabetes Series-July 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 19, 2024 at 04:00 PM EDT -
A Second Look: Discussing the results of a new observational study published in JAMA " Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity".
Tickers: LLY, NVO
Executed On: Jul 18, 2024 at 02:00 PM EDT -
Discussing the results of a new observational study published in JAMA " Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity".
Tickers: LLY, NVO
Executed On: Jul 18, 2024 at 01:00 PM EDT -
Speaking on the potential of Alzheon Inc's investigational oral agent ALZ-801/valiltramiprosate for Alzheimer's Disease
Tickers: ALZHEON INC., ESAIY, BIIB, LLY
Executed On: Jul 16, 2024 at 01:30 PM EDT -
Sharing your thoughts on the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy.
Tickers: GUTS, NVO, LLY
Executed On: Jul 16, 2024 at 10:00 AM EDT -
Obesity/Diabetes Series-July 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 12, 2024 at 04:00 PM EDT -
A Second Opinion: Evaluating tirzepatide's potential as a treatment for obstructive sleep apnea and obesity.
Ticker: LLY
Executed On: Jul 11, 2024 at 06:15 PM EDT -
Obesity/Diabetes Series-July 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 11, 2024 at 01:00 PM EDT -
Obesity/Diabetes Series-July 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 10, 2024 at 10:00 AM EDT -
A Second Look: Discussing how coverage, access, and pricing are evolving and being considered for GLP-1 obesity drugs, with a focus on Wegovy and Zebound.
Tickers: LLY, NVO
Executed On: Jul 02, 2024 at 02:30 PM EDT -
A Third Look: Discussing the 52-week data from the SYNERGY-NASH Phase 2 trial presented at the EASL Congress of Eli Lilly's tirzepatide in patients with MASH
Ticker: LLY
Executed On: Jun 28, 2024 at 11:00 AM EDT -
Evaluating tirzepatide's potential as a treatment for obstructive sleep apnea and obesity.
Ticker: LLY
Executed On: Jun 28, 2024 at 10:00 AM EDT -
A Second Look: Discussing the 52-week data from the SYNERGY-NASH Phase 2 trial presented at the EASL Congress of Eli Lilly's tirzepatide in patients with MASH
Ticker: LLY
Executed On: Jun 27, 2024 at 04:25 PM EDT -
Discussing how coverage, access, and pricing are evolving and being considered for GLP-1 obesity drugs, with a focus on Wegovy and Zebound.
Tickers: LLY, NVO
Executed On: Jun 27, 2024 at 03:00 PM EDT -
A Second View: Discussing the current state of GLP-1 medication compounding practices with a pharmacist
Tickers: LLY, HIMS, NVO
Executed On: Jun 27, 2024 at 07:00 AM EDT -
Discussing the 52-week data from the SYNERGY-NASH Phase 2 trial presented at the EASL Congress of Eli Lilly's tirzepatide in patients with MASH
Ticker: LLY
Executed On: Jun 26, 2024 at 05:00 PM EDT -
Obesity/Diabetes Series-June 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jun 25, 2024 at 08:00 AM EDT -
Obesity/Diabetes Series-June 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jun 21, 2024 at 08:00 AM EDT -
Discussing the current state of GLP-1 medication compounding practices with a pharmacist
Tickers: LLY, HIMS, NVO
Executed On: Jun 20, 2024 at 09:00 AM EDT -
A Third Opinion: Looking at Structure Therapeutics GLP-1 Receptor Agonist, GSBR-1290, and the results from their 12 week Phase 2a study
Tickers: GPCR, LLY, NVO
Executed On: Jun 13, 2024 at 03:10 PM EDT -
A Second Opinion: Looking at Structure Therapeutics GLP-1 Receptor Agonist, GSBR-1290, and the results from their 12 week Phase 2a study
Tickers: GPCR, LLY, NVO
Executed On: Jun 11, 2024 at 01:00 PM EDT -
Looking at Structure Therapeutics GLP-1 Receptor Agonist, GSBR-1290, and the results from their 12 week Phase 2a study
Tickers: GPCR, LLY, NVO
Executed On: Jun 10, 2024 at 03:00 PM EDT -
Obesity/Diabetes Series-June 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jun 06, 2024 at 11:00 AM EDT -
Obesity/Diabetes Series-June 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jun 06, 2024 at 09:00 AM EDT -
Digging into the results of the QWINT-2 and QWINT-4 phase 3 clinical trials by Eli Lilly evaluating once-weekly insulin efsitora alfa (efsitora) vs daily insulin in adults with type 2 diabetes
Ticker: LLY
Executed On: Jun 05, 2024 at 10:00 AM EDT -
A Third Look: Discussing GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity with an Oncologist
Tickers: LLY, NVO
Executed On: May 30, 2024 at 08:00 AM EDT -
Obesity/Diabetes Series-May 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: May 24, 2024 at 01:00 PM EDT -
Obesity/Diabetes Series-May 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: May 24, 2024 at 12:00 PM EDT -
Obesity/Diabetes Series-May 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: May 02, 2024 at 04:00 PM EDT -
Obesity/Diabetes Series-April 2024 (5): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 30, 2024 at 11:00 AM EDT -
A Third Discussion: Looking at the potential effects of GLP1 medications on Parkinson's Disease
Tickers: SNY, NVO, LLY
Executed On: Apr 25, 2024 at 05:15 PM EDT -
A Second Discussion: Looking at the potential effects of GLP1 medications on Parkinson's Disease
Tickers: SNY, NVO, LLY
Executed On: Apr 19, 2024 at 04:00 PM EDT -
A Second Look: Discussing GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity
Tickers: LLY, NVO
Executed On: Apr 19, 2024 at 09:00 AM EDT -
Looking at the potential effects of GLP1 medications on Parkinson's Disease
Tickers: SNY, NVO, LLY
Executed On: Apr 17, 2024 at 04:30 PM EDT -
Obesity/Diabetes Series-April 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 11, 2024 at 03:00 PM EDT -
Obesity/Diabetes Series-April 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 09, 2024 at 06:00 PM EDT -
Obesity/Diabetes Series-April 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 05, 2024 at 03:00 PM EDT -
Obesity/Diabetes Series-April 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 04, 2024 at 08:30 AM EDT -
A Second Look: Discussing the potential of Lilly's donanemab for Alzheimer's disease in light of the recent FDA delay.
Ticker: LLY
Executed On: Mar 26, 2024 at 04:30 PM EDT -
Discussing the potential of Lilly's donanemab for Alzheimer's disease in light of the recent FDA delay.
Ticker: LLY
Executed On: Mar 15, 2024 at 07:30 AM EDT -
Obesity/Diabetes Series-March 2024 (5): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 14, 2024 at 02:00 PM EDT -
Obesity/Diabetes Series-March 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 13, 2024 at 03:30 PM EDT -
A Third Look: Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LNTH, LLY, FUSN
Executed On: Mar 12, 2024 at 01:00 PM EDT -
Obesity/Diabetes Series-March 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 11, 2024 at 11:00 AM EDT -
Discussing GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity
Tickers: LLY, NVO
Executed On: Mar 07, 2024 at 01:40 PM EST -
Obesity/Diabetes Series-March 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 05, 2024 at 11:00 AM EST -
A Third View: Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Tickers: AMGN, NVO, LLY
Executed On: Mar 04, 2024 at 06:30 PM EST -
Obesity/Diabetes Series-March 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 04, 2024 at 10:00 AM EST -
A Second View: Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Tickers: AMGN, NVO, LLY
Executed On: Feb 29, 2024 at 10:30 AM EST -
Obesity/Diabetes Series-February 2024 (5): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 28, 2024 at 11:30 AM EST -
A Second Look: Discussing the potential of tirzepatide for overweight or obese adults with NASH and the results from Phase 2 SYNERGY-NASH study.
Ticker: LLY
Executed On: Feb 22, 2024 at 10:00 AM EST -
Obesity/Diabetes Series-February 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 16, 2024 at 09:00 AM EST -
3: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: BIIB, ESAIY, LLY
Executed On: Feb 15, 2024 at 05:00 PM EST -
Obesity/Diabetes Series-February 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 15, 2024 at 04:00 PM EST -
Discussing the potential of tirzepatide for overweight or obese adults with NASH and the results from Phase 2 SYNERGY-NASH study.
Ticker: LLY
Executed On: Feb 13, 2024 at 05:00 PM EST -
Obesity/Diabetes Series-February 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 12, 2024 at 12:00 PM EST -
Obesity/Diabetes Series-February 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 09, 2024 at 01:00 PM EST -
Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Tickers: AMGN, NVO, LLY
Executed On: Feb 07, 2024 at 02:00 PM EST -
A Second Look: Discussing the current radiopharmaceutical landscape for prostate cancer and different approaches to radioligand therapies in development.
Tickers: LNTH, NVS, LLY, FUSN
Executed On: Feb 02, 2024 at 09:00 AM EST -
A Second Look: Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LNTH, LLY, FUSN
Executed On: Feb 01, 2024 at 04:30 PM EST -
A Second View: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: LLY, ESAIY, BIIB
Executed On: Jan 26, 2024 at 01:00 PM EST -
Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LLY, LNTH, FUSN
Executed On: Jan 26, 2024 at 08:00 AM EST -
Discussing the current radiopharmaceutical landscape for prostate cancer and different approaches to radioligand therapies in development.
Tickers: LNTH, NVS, LLY, FUSN
Executed On: Jan 24, 2024 at 12:30 PM EST -
A Third Look: Discussing the recent FDA accelerated approval for Jaypirca from Eli Lilly for treating CLL/SLL in patients that received at least two prior lines of therapy based on the study BRUIN
Ticker: LLY
Executed On: Jan 19, 2024 at 08:00 AM EST -
A Second Opinion: Looking at the potential of Altimmune's pemvidutide, a GLP-1/glucagon dual receptor agonist for patients with obesity
Tickers: ALT, LLY, NVO
Executed On: Jan 18, 2024 at 10:00 AM EST -
Obesity/Diabetes Series: A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jan 18, 2024 at 08:00 AM EST -
A Third Look: Discussing the results from the Phase 1 study evaluating the safety and tolerability of Lepodisiran in healthy participants with high lipoprotein(a) levels
Ticker: LLY
Executed On: Jan 16, 2024 at 12:00 PM EST -
Investigating the impact of GLP-1 medications on the progression and management of diabetic retinopathy.
Tickers: LLY, NVO
Executed On: Jan 16, 2024 at 10:30 AM EST -
A Second Look: Discussing the recent FDA accelerated approval for Jaypirca from Eli Lilly for treating CLL/SLL in patients that received at least two prior lines of therapy based on the study BRUIN
Ticker: LLY
Executed On: Jan 11, 2024 at 02:00 PM EST -
Looking at the potential of Altimmune's pemvidutide, a GLP-1/glucagon dual receptor agonist for patients with obesity
Tickers: ALT, LLY, NVO
Executed On: Jan 11, 2024 at 09:30 AM EST -
Discussing the recent FDA accelerated approval for Jaypirca from Eli Lilly for treating CLL/SLL in patients that received at least two prior lines of therapy based on the study BRUIN
Ticker: LLY
Executed On: Jan 10, 2024 at 04:30 PM EST -
Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: ESAIY, BIIB, LLY
Executed On: Jan 05, 2024 at 03:00 PM EST -
A Third View: Dissecting the results from the SURMOUNT-4 clinical trial regarding weight gain after the discontinuation of Zepbound (tirzepatide).
Ticker: LLY
Executed On: Jan 05, 2024 at 07:00 AM EST -
A Second Look: Discussing the potential of BI 690517 in combination with Jardiance for reducing urinary albumin-to-creatinine ratio (UACR) in patients with CKD
Tickers: BOEHRINGER INGELHEIM, LLY
Executed On: Dec 21, 2023 at 04:00 PM EST -
Discussing the potential of BI 690517 in combination with Jardiance for reducing urinary albumin-to-creatinine ratio (UACR) in patients with CKD
Tickers: BOEHRINGER INGELHEIM, LLY
Executed On: Dec 21, 2023 at 08:30 AM EST -
A Second View: Dissecting the results from the SURMOUNT-4 clinical trial regarding weight gain after the discontinuation of Zepbound (tirzepatide).
Ticker: LLY
Executed On: Dec 20, 2023 at 09:30 AM EST -
Dissecting the results from the SURMOUNT-4 clinical trial regarding weight gain after the discontinuation of Zepbound (tirzepatide).
Ticker: LLY
Executed On: Dec 14, 2023 at 11:15 AM EST -
A Third Look: Discussing the potential of Omvoh, an interleukin-23p19 antagonist developed by Eli Lilly for the treatment of patients with moderately to severely active ulcerative colitis.
Ticker: LLY
Executed On: Dec 08, 2023 at 12:30 PM EST -
A Second Look: Discussing the results from the Phase 1 study evaluating the safety and tolerability of Lepodisiran in healthy participants with high lipoprotein(a) levels
Ticker: LLY
Executed On: Nov 29, 2023 at 04:30 PM EST -
A third look at the use of GLP-1 agonists and factors affecting prescribing patterns and insurance coverage for these agents with an Endocrinologist.
Tickers: LLY, NVO
Executed On: Nov 29, 2023 at 02:45 PM EST -
Discussing the results from the Phase 1 study evaluating the safety and tolerability of Lepodisiran in healthy participants with high lipoprotein(a) levels
Ticker: LLY
Executed On: Nov 28, 2023 at 05:00 PM EST -
A Second Look: Discussing the potential of Omvoh, an interleukin-23p19 antagonist developed by Eli Lilly for the treatment of patients with moderately to severely active ulcerative colitis.
Ticker: LLY
Executed On: Nov 22, 2023 at 03:00 PM EST -
A second look at the use of GLP-1 agonists and factors affecting prescribing patterns and insurance coverage for these agents with an Endocrinologist.
Tickers: LLY, NVO
Executed On: Nov 22, 2023 at 12:00 PM EST -
Digging into the results from the phase 3 VIVID-1 clinical trial evaluating mirikizumab in patients with moderately to severely active Crohn's disease.
Ticker: LLY
Executed On: Nov 22, 2023 at 11:00 AM EST -
A look at the use of GLP-1 agonists and factors affecting prescribing patterns and insurance coverage for these agents with an Endocrinologist.
Tickers: LLY, NVO
Executed On: Nov 21, 2023 at 03:00 PM EST -
A Second Payor Perspective: Discussing how access and pricing are being considered for GLP-1 obesity drugs with a focus on Wegovy and Zebound
Tickers: LLY, NVO
Executed On: Nov 21, 2023 at 01:00 PM EST -
Discussing the data presented at the CTAD conference for Lilly's Donanemab from the TRAILBLAZER-ALZ 2 study in Early Symptomatic Alzheimer’s Disease
Ticker: LLY
Executed On: Nov 17, 2023 at 03:00 PM EST -
Discussing the potential of Omvoh, an interleukin-23p19 antagonist developed by Eli Lilly for the treatment of patients with moderately to severely active ulcerative colitis.
Ticker: LLY
Executed On: Nov 17, 2023 at 08:00 AM EST -
A Payor Perspective: Discussing how access and pricing are being considered for GLP-1 obesity drugs with a focus on Wegovy and Zebound
Tickers: LLY, NVO
Executed On: Nov 16, 2023 at 01:00 PM EST -
A look at the data presented at the CTAD conference for Eisai's and Biogen's LEQEMBI and Lilly's Donanemab in Alzheimer’s Disease.
Tickers: LLY, BIIB
Executed On: Nov 08, 2023 at 03:30 PM EST -
A Third Look: Discussing the recent announcement from Lilly regarding Lebrikizumab monthly maintenance dosing maintained durable skin clearance in their Phase 3 monotherapy atopic dermatitis trials
Ticker: LLY
Executed On: Nov 02, 2023 at 12:30 PM EDT -
A Second Look: Discussing the recent announcement from Lilly regarding Lebrikizumab monthly maintenance dosing maintained durable skin clearance in their Phase 3 monotherapy atopic dermatitis trials
Ticker: LLY
Executed On: Nov 01, 2023 at 02:00 PM EDT -
A Second Look: Discussing the results from the SURMOUNT-4 study on tirzepatide
Ticker: LLY
Executed On: Oct 31, 2023 at 03:30 PM EDT -
A Third Look: Discussing the results from the SURMOUNT-4 study on tirzepatide
Ticker: LLY
Executed On: Oct 31, 2023 at 08:30 AM EDT -
A Third View: Discussing the GI related side effects of GLP-1 agonists
Tickers: LLY, NVO
Executed On: Oct 27, 2023 at 12:00 PM EDT -
Discussing the results from the SURMOUNT-4 study on tirzepatide
Ticker: LLY
Executed On: Oct 26, 2023 at 08:30 AM EDT -
Discussing the recent announcement from Lilly regarding Lebrikizumab monthly maintenance dosing maintained durable skin clearance in their Phase 3 monotherapy atopic dermatitis trials
Ticker: LLY
Executed On: Oct 25, 2023 at 01:00 PM EDT -
A Third View: Discussing the recent label expansion of Jardiance (empagliflozin) to patients with Chronic kidney disease and type 2 diabetes
Ticker: LLY
Executed On: Oct 18, 2023 at 02:00 PM EDT -
A Second View: Discussing the recent label expansion of Jardiance (empagliflozin) to patients with Chronic kidney disease and type 2 diabetes
Ticker: LLY
Executed On: Oct 16, 2023 at 10:00 AM EDT -
A Second View: Discussing the GI related side effects of GLP-1 agonists
Tickers: NVO, LLY
Executed On: Oct 13, 2023 at 04:00 PM EDT -
Looking at the topline results from the LIBRETTO-531 study evaluating Retevmo versus cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic thyroid cancer (MTC)
Ticker: LLY
Executed On: Oct 11, 2023 at 09:00 AM EDT -
A second look at how payers within the U.S. are strategizing the reimbursement of obesity drugs such as semaglutide and tirzepatide.
Tickers: LLY, NVO
Executed On: Oct 06, 2023 at 02:30 PM EDT -
Discussing the GI related side effects of GLP-1 agonists
Tickers: NVO, LLY
Executed On: Oct 06, 2023 at 01:00 PM EDT -
A Second Look: Investigating the recent phase 3 DINAMO clinical trial data on Jardiance (empagliflozin) and Tradjenta (linagliptin) in pediatric patients with type-2 diabetes.
Tickers: LLY, Boehringer Ingelheim
Executed On: Sep 29, 2023 at 04:00 PM EDT -
Discussing the recent label expansion of Jardiance (empagliflozin) to patients with Chronic kidney disease and type 2 diabetes
Ticker: LLY
Executed On: Sep 29, 2023 at 02:00 PM EDT -
Discussing how Eli Lilly's Jaypirca (pirtobrutinib) fits into the treatment landscape for mantle cell lymphoma (MCL)
Ticker: LLY
Executed On: Sep 21, 2023 at 05:00 PM EDT -
A Second prescriber check in to discuss how Eli Lilly's Jaypirca (pirtobrutinib) fits into the treatment landscape for mantle cell lymphoma (MCL)
Ticker: LLY
Executed On: Sep 12, 2023 at 03:30 PM EDT -
Prescriber check in to discuss how Eli Lilly's Jaypirca (pirtobrutinib) fits into the treatment landscape for mantle cell lymphoma (MCL)
Ticker: LLY
Executed On: Sep 05, 2023 at 04:00 PM EDT -
A Fourth View: Looking at the Alzheimer's Landscape with a focus on Lilly's Donanemab compared to Biogen's Leqembi.
Tickers: LLY, BIIB
Executed On: Aug 24, 2023 at 10:00 AM EDT -
Investigating the recent phase 3 DINAMO clinical trial data on Jardiance (empagliflozin) and Tradjenta (linagliptin) in pediatric patients with type-2 diabetes.
Tickers: LLY, Boehringer Ingelheim
Executed On: Aug 23, 2023 at 01:00 PM EDT -
A Second Look: Discussing how US psychiatrists prescribe Wegovy to battle medication-induced weight gain
Tickers: NVO, LLY
Executed On: Aug 17, 2023 at 10:30 AM EDT -
Discussing how US psychiatrists prescribe Wegovy to battle medication-induced weight gain
Tickers: NVO, LLY
Executed On: Aug 17, 2023 at 09:45 AM EDT -
A look at how payers within the U.S. are strategizing the reimbursement of obesity drugs such as semaglutide and tirzepatide.
Tickers: LLY, NVO
Executed On: Aug 11, 2023 at 09:30 AM EDT -
A Third View: Looking at the Alzheimer's Landscape with a focus on Lilly's Donanemab compared to Biogen's Leqembi.
Tickers: LLY, BIIB
Executed On: Aug 11, 2023 at 09:00 AM EDT -
A third look: Discussing the potential of tirzepatide in patients with obesity and the recent results from the Phase 3 SURMOUNT 3 and 4 studies with an endocrinologist
Ticker: LLY
Executed On: Aug 08, 2023 at 09:30 AM EDT -
A second look: Discussing the potential of tirzepatide in patients with obesity and the recent results from the Phase 3 SURMOUNT 3 and 4 studies with an endocrinologist
Ticker: LLY
Executed On: Aug 07, 2023 at 07:30 AM EDT -
Discussing the potential of tirzepatide in patients with obesity and the recent results from the Phase 3 SURMOUNT 3 and 4 studies in adults with obesity
Ticker: LLY
Executed On: Aug 02, 2023 at 03:00 PM EDT -
A second look: Discussing the potential of Orforglipron, a once daily oral GLP-1 receptor agonist, and the Phase 2 Study in obesity recently presented at ADA 2023.
Ticker: LLY
Executed On: Jul 28, 2023 at 11:00 AM EDT -
Discussing the potential of Orforglipron, a once daily oral GLP-1 receptor agonist, and the Phase 2 Study in obesity recently presented at ADA 2023.
Ticker: LLY
Executed On: Jul 28, 2023 at 08:00 AM EDT -
A Second View: Looking at the Alzheimer's Landscape with a focus on Lilly's Donanemab compared to Biogen's Leqembi.
Tickers: LLY, BIIB
Executed On: Jul 07, 2023 at 02:30 PM EDT -
A Second View: Understanding the results of the phase 3 SURMOUNT-2 clinical of Eli Lilly's Mounjaro (Tirzepatide) for use in weight management released at ADA 2023
Ticker: LLY
Executed On: Jun 30, 2023 at 09:00 AM EDT -
Understanding the results of the phase 3 SURMOUNT-2 clinical of Eli Lilly's Mounjaro (Tirzepatide) for use in weight management released at ADA 2023
Ticker: LLY
Executed On: Jun 30, 2023 at 08:30 AM EDT -
A second look: Examining the potential of Lilly's Triple Hormone-Receptor Agonist, Retatrutide (LY3437943), and it's Phase 2 results in obesity presented at the ADA Conference
Ticker: LLY
Executed On: Jun 30, 2023 at 08:00 AM EDT -
Examining the potential of Lilly's Triple Hormone-Receptor Agonist, Retatrutide (LY3437943), and it's Phase 2 results in obesity presented at the ADA Conference
Ticker: LLY
Executed On: Jun 28, 2023 at 03:30 PM EDT -
A third opinion: Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Tickers: LLY, AZN, NVO
Executed On: Jun 06, 2023 at 04:30 PM EDT -
Looking at the Alzheimer's Landscape with a focus on Lilly's Donanemab compared to Biogen's Leqembi.
Tickers: LLY, BIIB
Executed On: May 23, 2023 at 01:00 PM EDT -
A second opinion: Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Tickers: LLY, AZN, NVO
Executed On: May 11, 2023 at 01:00 PM EDT -
Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Tickers: LLY, AZN, NVO
Executed On: May 10, 2023 at 06:15 PM EDT -
A second look: Examining the potential of Eli Lillys' KRAS G12C inhibitor, LY3537982, in KRAS G12C–mutant advanced solid tumors with a focus on the Phase 1 LOXO-RAS-20001 study presented at AACR 2023
Ticker: LLY
Executed On: Apr 25, 2023 at 05:30 PM EDT -
Examining the potential of Eli Lillys' KRAS G12C inhibitor, LY3537982, in KRAS G12C–mutant advanced solid tumors with a focus on the Phase 1 LOXO-RAS-20001 study presented at AACR 2023
Tickers: LLY, AMGN, MRTX
Executed On: Apr 25, 2023 at 04:30 PM EDT -
A Third Look: Examining the potential use of Eli Lilly's Jaypirca (pirtobrutinib) in light of the FDA Approval for mantle cell lymphoma
Ticker: LLY
Executed On: Apr 21, 2023 at 08:00 AM EDT -
A Third View: Discussing Remternetug (LY3372993), an investigational monoclonal antibody being developed by Eli Lilly for the treatment of Alzheimer's Disease
Ticker: LLY
Executed On: Apr 18, 2023 at 05:45 PM EDT -
A Second View: Discussing Remternetug (LY3372993), an investigational monoclonal antibody being developed by Eli Lilly for the treatment of Alzheimer's Disease
Ticker: LLY
Executed On: Apr 13, 2023 at 05:45 PM EDT -
A Second Look: Examining the potential use of Eli Lilly's Jaypirca (pirtobrutinib) in light of the FDA Approval for mantle cell lymphoma
Ticker: LLY
Executed On: Apr 13, 2023 at 05:00 PM EDT -
A third look: Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for the potential treatment of obesity and various metabolic disorders
Tickers: VKTX, LLY
Executed On: Apr 10, 2023 at 01:00 PM EDT -
Discussing Remternetug (LY3372993), an investigational monoclonal antibody being developed by Eli Lilly for the treatment of Alzheimer's Disease
Ticker: LLY
Executed On: Apr 06, 2023 at 04:15 PM EDT -
A second look: Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for the potential treatment of obesity and various metabolic disorders
Tickers: VKTX, LLY
Executed On: Apr 06, 2023 at 02:00 PM EDT -
Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for the potential treatment of obesity and various metabolic disorders
Tickers: VKTX, LLY
Executed On: Apr 04, 2023 at 10:45 AM EDT -
Examining the potential use of Eli Lilly's Jaypirca (pirtobrutinib) in light of the FDA Approval for mantle cell lymphoma
Ticker: LLY
Executed On: Mar 06, 2023 at 04:40 PM EST -
A Second Look: Examining the current use of Dapagliflozin (Farxiga) in the heart failure treatment landscape
Tickers: AZN, LLY
Executed On: Nov 21, 2022 at 01:00 PM EST -
Examining the current use of Dapagliflozin (Farxiga) in the heart failure treatment landscape
Tickers: AZN, LLY
Executed On: Nov 03, 2022 at 12:00 PM EDT -
A third discussion on the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: ALT, LLY, NVO
Executed On: Nov 03, 2022 at 11:30 AM EDT -
A second discussion on the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: ALT, LLY, NVO
Executed On: Nov 01, 2022 at 03:00 PM EDT -
A Third Look: Understanding the Landscape of Type-2 Diabetes Treatments and the prevalence of Lilly's Mounjaro.
Tickers: LLY, NVO
Executed On: Nov 01, 2022 at 02:00 PM EDT -
A discussion about managing patients with obesity and other overweight-related health problems. Focusing on the standard of care and the potential of Eli Lily's diabetes/weight loss drug, tirzepatide
Tickers: LLY, NVO
Executed On: Oct 31, 2022 at 03:30 PM EDT -
Discussing the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: ALT, LLY, NVO
Executed On: Oct 28, 2022 at 02:45 PM EDT -
A Second View: Understanding the Landscape of Type-2 Diabetes Treatments and the prevalence of Lilly's Mounjaro.
Tickers: LLY, NVO, AZN
Executed On: Oct 20, 2022 at 09:30 AM EDT -
Understanding the Landscape of Type-2 Diabetes Treatments and the prevalence of Lilly's Mounjaro.
Tickers: LLY, NVO
Executed On: Oct 19, 2022 at 10:00 AM EDT -
A Third View: Discussing the FDA Approval of Oluminant for treatment of Alopecia Areata
Tickers: LLY, INCY
Executed On: Jun 23, 2022 at 03:00 PM EDT -
A Second View: Discussing the FDA Approval of Oluminant for treatment of Alopecia Areata
Tickers: LLY, INCY
Executed On: Jun 17, 2022 at 01:00 PM EDT -
Discussing the FDA Approval of Oluminant for treatment of Alopecia Areata
Tickers: LLY, INCY
Executed On: Jun 16, 2022 at 05:30 PM EDT -
A Third View: A look at the potential of LY3462817 (Peresolimab) - a PD-1 Antibody Agonist in Rheumatoid Arthritis
Ticker: LLY
Executed On: Jun 10, 2022 at 12:00 PM EDT -
A Second View: A look at the potential of LY3462817 (Peresolimab) - a PD-1 Antibody Agonist in Rheumatoid Arthritis
Ticker: LLY
Executed On: Jun 09, 2022 at 10:00 AM EDT -
A look at the potential of LY3462817 (Peresolimab) - a PD-1 Antibody Agonist in Rheumatoid Arthritis
Ticker: LLY
Executed On: Jun 08, 2022 at 11:00 AM EDT -
Another look at Tirzepatide, how it compares to semaglutide, and the potential in Type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 25, 2022 at 04:00 PM EDT -
A look at the upcoming PDUFA of tirzepatide and possible implications in Type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 21, 2022 at 03:00 PM EDT
Upcoming & Overdue Catalysts (LLY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (LLY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
